Evaluation of the cost saving potential of introducing Benepali® and Flixabi® on the European and Italian markets

Cristina Negrini, Emi Psachoulia

DOI: https://doi.org/10.7175/fe.v18i1.1330

Abstract

INTRODUCTION: Biosimilar products play an important role in improving the access to biological medicines for an increased number of patients and enhancing the financial sustainability of the health systems.

AIM: To assess the cost saving potential associated with the introduction of two biosimilars (Benepali® and Flixabi®) vs. their respective reference biological products on the European and Italian markets.

METHODS: A budget impact model was developed to estimate the cost saving of the hypothetical introduction of Benepali® and Flixabi® vs. Enbrel® and Remicade®, respectively, in three European countries. The analysis was conducted from the payer perspective, over a 3-year period. In addition, the same model was used to assess the impact of Benepali® vs. Enbrel® in three Italian regions over a 2-year period. The model compares the costs associated with the current treatment patterns, used to manage patients with all the conditions which Benepali® and Flixabi® are authorized for, with that of a hypothetical treatment pattern in which biosimilar products have been introduced. Only direct costs associated with the drug acquisition were considered. The model was constructed using published country- or region-specific data, where available. Annual drug acquisition costs were calculated using the dosing information from SPCs and country-/region-specific price lists.

RESULTS: The introduction of Benepali® and Flixabi® in the biologic therapeutic setting of three European countries resulted in substantial cost savings across the entire scenario, with different penetration over a 3-year period. Similarly, over a 2-year horizon, the introduction of Benepali® in the biologic therapeutic setting of three Italian regions resulted in significant cost savings. In all cases, the greater savings were observed in the scenario where the biosimilars’ penetration was higher.

CONCLUSIONS: The introduction of Benepali® and Flixabi® has a substantial cost saving potential for the Italian and European health systems, and the budget impact is sensitive to the uptake rates of the biosimilars market.

Keywords

Biosimilars; Etanercept; Infliximab; Cost saving

Full Text

HTML PDF

References

  • European Medicine Agency (EMA). Biosimilar medicines. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/general/general_content_001832.jsp (last accessed July 2017)
  • Cantelli Forti G, Rossi F. Revisione della posizione sui farmaci biosimilari da parte della Società Italiana di Farmacologia: working paper 2016. SIFO, 2016. Available at: http://www.sifweb.org/docs/sif_position_paper_working_paper_biosimilari_set16.pdf (last accessed March 2017)
  • Aitken M. Delivering on the potential of biosimilar medicines. The role of functioning competitive markets. IMS. IMS Institute for Healthcare Informatics, 2016. Available at: http://www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20Briefs/Documents/IMS_Institute_Biosimilar_Brief_March_2016.pdf (last accessed March 2017)
  • Acha V, Mestre-Ferrandiz J. Translating European regulatory approval into healthcare uptake for biosimilars: the second translational gap. Technology Analysis & Strategic Management 2017; 29: 263-75; https://doi.org/10.1080/09537325.2017.1285396
  • Agenzia Italiana del Farmaco (AIFA). Secondo Concept Paper Aifa Sui Farmaci Biosimilari. AIFA, 2016. Available at: http://www.aifa.gov.it/sites/default/files/Secondo_Concept_Paper_AIFA_BIOSIMILARI.pdf (last accessed March 2017)
  • Psachoulia E, Martin-Rinconada C, Levysohn A. Potential impact of the biosimilars introduction of 3 anti-TNFs in the European market. ISPOR 22nd Annual International Meeting. Boston, May 20-24, 2017
  • Reiland JB, Freischem B; Roediger A. What pricing and reimbursement policies to use for off-patent biologicals in Europe? – results from the second EBE biological medicines policy survey. GaBI Journal 2017; 6: 61-78; https://doi.org/10.5639/gabij.2017.0602.014
  • Bocquet F, Loubière A, Fusier I, et al. Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience. Pharmacoeconomics 2016; 34: 1173-86
  • Bocquet F, Paubel P, Fusier I, et al. Biosimilar granulocyte colony-stimulating factor uptakes in the EU-5 markets: a descriptive analysis. Appl Health Econ Health Policy 2014; 12: 315-26; https://doi.org/10.1007/s40258-014-0087-8
  • Bocquet F, Paubel P, Fusier I, et al. Biosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experience. Appl Health Econ Health Policy 2015; 13: 47-59; https://doi.org/10.1007/s40258-014-0125-6
  • European Medicines Agency (EMA). Benepali – European Public Assessment Report (EPAR). Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004007/human_med_001944.jsp&mid=WC0b01ac058001d124 (last accessed March 2017)
  • European Medicines Agency (EMA). Flixabi – European Public Assessment Report (EPAR). Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004020/human_med_001980.jsp&mid=WC0b01ac058001d124 (last accessed March 2017)
  • Committee for Medicinal Products for Human Use (CHMP). Summary of opinion – Remsima. EMA/CHMP/363689/2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002576/WC500144832.pdf (last accessed March 2017)
  • Committee for Medicinal Products for Human Use (CHMP). Summary of opinion – Inflectra. EMA/CHMP/364710/2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002778/WC500144831.pdf (last accessed March 2017)
  • IMS Health. Available at: www.imshealth.com (last accessed September 2016)
  • Groupement pour l’Elaboration et la Réalisation de Statistiques. Available at: www.gie-gers.fr/ (last accessed September 2016)
  • Reveal. Pharmaceutical Statistics. Available at: http://www.reveal.se/en/pharmaceutical-statistics/ (last accessed September 2016)
  • Codifa. L’informatore farmaceutico. Available at: www.codifa.it (last accessed September 2016)
  • Arrêté du 10 mai 2016 modifiant la liste des spécialités pharmaceutiques remboursables aux assurés sociaux. Journal Officiel de la République Française n°0120 du 25 Mai 2016 texte n° 18
  • The Dental and Pharmaceutical Benefits Agency – TLV. Available at: http://www.tlv.se/ (last accessed June 2016)
  • XE – Live exchange rates. Available at: www.xe.com (last accessed June 2016)
  • Biogen elaborations based on IMS HEALTH Data AIB SPLIT for the Immunology Market MAT 3-2016
  • L’Assurance Maladie en ligne. Tarif Responsabilité infliximab. Available at: http://www.codage.ext.cnamts.fr/codif/bdm_it/index.php?p_site=AMELI (last accessed June 2016)
  • MIMS – Database of prescription and generic drugs, clinical guidelines. Available at: http://www.mims.co.uk/drugs/musculoskeletal-disorders/rheumatoid-arthritis-other-autoimmune-disorders (last accessed June 2016)
  • IMS Institute for Healthcare Informatics. Assessing biosimilar uptake and competition in European Market, 2014. Available at: https://www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20Briefs/Assessing_biosimilar_uptake_and_competition_in_European_markets.pdf (last accessed March 2017)
  • Haustein R, de Millas C, Höer A, et al. Saving money in the European healthcare systems with biosimilars. Generics and Biosimilars Initiative Journal (GaBI Journal). 2012; 1: 120-6; https://doi.org/10.5639/gabij.2012.0103-4.036
  • Becciolini A, Psachoulia E, Biggioggero M, et al. The introduction of etanercept biosimilar in the practice of a tertiary rheumatologic Centre in Italy: a budget impact model. ISPOR 19th Annual European Congress. Vienna, 29 October-2 November 2016
  • Psachoulia E, Casahorrán V. Estimation of The Budget Saving Potential Due To The Introduction of Benepali®, An Etanercept Biosimilar, For The Treatment of All Licensed Adult Etanercept Indications In Spain. Value Health 2016; 19: A533-4; https://doi.org/10.1016/j.jval.2016.09.1088
  • Jha A, Upton A, Dunlop WC, et al. The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries. Adv Ther 2015; 32: 742-56; https://doi.org/10.1007/s12325-015-0233-1
  • Brodszky V, Baji P, Balogh O, et al. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries. Eur J Health Econ 2014; 15 Suppl 1: S65-71; https://doi.org/10.1007/s10198-014-0595-3
  • Psachoulia E, Keady S. Evaluation of The Cost Saving Potential of Introducing An Etanercept Biosimilar (Benepali®) For The Treatment of All Licensed Adult Etanercept Indications In The UK. . Value Health 2016; 19: A533
  • Mestre-Ferrandiz J, Towse A, Berdud M. Biosimilars: How Can Payers Get Long-Term Savings? Pharmacoeconomics 2016; 34: 609-16; https://doi.org/10.1007/s40273-015-0380-x
  • GfK Market Access on behalf of the European Biosimilars Group (EBG). Factors Supporting a Sustainable European Biosimilar Medicines Market. 2014. Available at: http://www.medicinesforeurope.com/wp-content/uploads/2016/03/GfK_Final_Report-_Factors_Supporting_a_Sustainable_European_Biosimilar_Medicines_Market.pdf (last accessed July 2017)

Statistics

Abstract: 3189 views
HTML: 940 views
PDF: 846 views

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.